Date: 3 November 2026
Time: 17:30 – 20:30
Venue: 406 Cambridge Science Park Milton Rd, Milton, Cambridge CB4 0WW
Details:
Hosted by Venner Shipley on 14 July at their site on Cambridge Science Park will spotlight AI in Biotech, and aims to provide insight on how AI driven companies are evolving through partnerships, consolidation and clinical delivery.
Meet the team: Our CEO, Matt Segall, is giving a talk
Title: Delivering value from AI in drug discovery: From algorithm to adoption
If you’re attending, we’d love to connect!
CEO and Company Director
Matt has a Master of Science in Computation from the University of Oxford and a PhD in Theoretical Physics from the University of Cambridge.
As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery.
In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform.
Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.
New user interface provides visual insights to guide compound optimisation CAMBRIDGE, UK, 24 March 2026 – Optibrium, a leading developer of software and AI solutions for molecular design, today…
Newly created role underscores commitment to customer-driven research and scientific excellence CAMBRIDGE, UK, 13 January 2026 – Optibrium, a leading developer of software and AI…
Latest release accelerates hit-to-candidate progression by keeping teams aligned, eliminating inefficiencies and enabling better prioritisation decisions CAMBRIDGE, UK, 04 November…
